Similar articles for PMID: 32646877

1

Cite

Share

Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.

Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Czernin J, et al. J Nucl Med. 2021 Feb;62(2):228-231. doi: 10.2967/jnumed.120.246041. Epub 2020 Jul 9. J Nucl Med. 2021. PMID: 32646877

Cite

Share

2

Cite

Share

Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.

Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Current K, et al. Clin Cancer Res. 2020 Jun 15;26(12):2946-2955. doi: 10.1158/1078-0432.CCR-19-1485. Epub 2020 Jan 13. Clin Cancer Res. 2020. PMID: 31932492 Free PMC article.

Cite

Share

3

Cite

Share

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Lückerath K, et al. EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z. EJNMMI Res. 2018. PMID: 30374743 Free PMC article.

Cite

Share

4

Cite

Share

Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Fendler WP, et al. J Nucl Med. 2017 Nov;58(11):1786-1792. doi: 10.2967/jnumed.117.193359. Epub 2017 May 25. J Nucl Med. 2017. PMID: 28546332 Free PMC article.

Cite

Share

5

Cite

Share

Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Lückerath K, et al. J Nucl Med. 2018 Sep;59(9):1392-1397. doi: 10.2967/jnumed.118.207704. Epub 2018 Mar 30. J Nucl Med. 2018. PMID: 29602819 Free PMC article.

Cite

Share

6

Cite

Share

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.

Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR. Miyahira AK, et al. Prostate. 2020 Nov;80(15):1273-1296. doi: 10.1002/pros.24056. Epub 2020 Aug 31. Prostate. 2020. PMID: 32865839 Review.

Cite

Share

7

Cite

Share

Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.

Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN. Dudzinski SO, et al. J Immunother Cancer. 2019 Aug 14;7(1):218. doi: 10.1186/s40425-019-0704-z. J Immunother Cancer. 2019. PMID: 31412954 Free PMC article.

Cite

Share

8

Cite

Share

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8⁺ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM. Zhang Q, et al. Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Eur Urol. 2018. PMID: 29275833 Free PMC article. Review.

Cite

Share

9

Cite

Share

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE. Benzon B, et al. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):126-136. doi: 10.1038/s41391-018-0035-z. Epub 2018 Mar 20. Prostate Cancer Prostatic Dis. 2018. PMID: 29556048 Free PMC article.

Cite

Share

10

Cite

Share

CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.

Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A. Kristensen LK, et al. Theranostics. 2019 Oct 18;9(26):8221-8238. doi: 10.7150/thno.37513. eCollection 2019. Theranostics. 2019. PMID: 31754392 Free PMC article.

Cite

Share